Mind Medicine Gets FDA Clearance for IND Application for Anxiety Treatment
By Chris Wack
Mind Medicine Inc. said the U.S. Food and Drug Administration
has cleared its investigational new-drug application, allowing the
company's Phase 2b dose-optimization trial of MM-120 for the
treatment of generalized anxiety disorder to proceed.
The biopharmaceutical company said the previously announced
clinical hold on the IND was lifted following its rapid responses
for additional information related to the participant monitoring
protocol in the coming study.
Mind Medicine said it is working with study investigators and
clinical trial sites to prepare for participant enrollment, which
is expected to start in early 2022.
Mind Medicine shares were up 16% to $1.08 in premarket
Write to Chris Wack at email@example.com
(END) Dow Jones Newswires
January 25, 2022 08:02 ET (13:02 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.